31,043 Shares in Johnson & Johnson $JNJ Bought by Clear Trail Advisors LLC

Key Points

• Clear Trail Advisors LLC initiated a new position of 31,043 shares in Johnson & Johnson in Q4 (≈$6.42M), representing about 1.5% of the fund’s portfolio and the stock's 18th largest holding.
• Company insiders have been net sellers recently — EVP Vanessa Broadhurst sold 6,197 shares and EVP Timothy Schmid sold 1,322 shares, with insiders disposing of 30,142 shares (~$7.36M) over the past 90 days; insiders now own about 0.16% of JNJ.
• Key positive developments include an overturned ~$950M punitive‑damages award and encouraging clinical/medtech updates (strong Phase 1 erdafitinib results and an FDA ophthalmology approval), while analysts collectively rate JNJ a "Moderate Buy" with an average target near $236.91.

Clear Trail Advisors LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 31,043 shares of the company's stock, valued at approximately $6,424,000. Johnson & Johnson accounts for about 1.5% of Clear Trail Advisors LLC's portfolio, making the stock its 18th biggest holding.

Several other large investors have also added to or reduced their stakes in JNJ. Abich Financial Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $26,000. Evolution Wealth Management Inc. purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $27,000. Clayton Financial Group LLC acquired a new position in Johnson & Johnson in the 3rd quarter worth approximately $28,000. Semmax Financial Advisors Inc. raised its position in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after buying an additional 72 shares during the last quarter. Finally, Turning Point Benefit Group Inc. acquired a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $41,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the firm's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 over the last 90 days. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Freedom Capital downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Friday, January 16th. BMO Capital Markets reissued an "outperform" rating on shares of Johnson & Johnson in a report on Thursday, December 11th. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $225.00 to $250.00 and gave the company a "neutral" rating in a research report on Thursday, March 5th. Royal Bank Of Canada increased their price target on Johnson & Johnson from $240.00 to $255.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 3rd. Finally, Weiss Ratings reiterated a "buy (b)" rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $236.91.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $239.93 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The company has a 50 day moving average price of $236.58 and a 200-day moving average price of $209.82. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71. The firm has a market cap of $577.90 billion, a price-to-earnings ratio of 21.71, a price-to-earnings-growth ratio of 2.32 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson's dividend payout ratio is presently 47.06%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Punitive damages of about $950 million in a talc-related case were overturned, materially reducing near‑term litigation exposure and uncertainty for JNJ. Punitive Damages Award Overturned
• Positive Sentiment: Phase 1 results for an extended‑release erdafitinib delivery system in non‑muscle‑invasive bladder cancer showed very high response rates (reportedly ~89%), supporting upside to the Innovative Medicines pipeline if later‑stage data confirm benefits. Bladder Cancer Trial Results
• Positive Sentiment: Medtech momentum: JNJ reported FDA approval for the TECNIS PureSee intraocular lens and highlighted procedure‑area advances that could add recurring, higher‑margin revenue in ophthalmology and procedures. Procedure & Vision Advances
• Positive Sentiment: Technical and analyst sentiment remains constructive: JNJ has traded above its 50‑ and 200‑day moving averages for months and brokers/media pieces are highlighting it as a defensive, innovation‑led buy, supporting demand from yield‑and‑quality oriented investors. Technical/Broker Commentary
• Positive Sentiment: Partnerships/pipeline expansion: a collaboration (Protagonist) was highlighted as part of JNJ’s effort to compete in immunology, which could bolster longer‑term growth prospects. Protagonist Partnership
• Neutral Sentiment: Market narratives and strategy pieces continue to cast JNJ as a defensive, dividend‑king stock with innovation upside — useful framing for long‑term investors but less directly catalytic than clinical or legal events.
• Negative Sentiment: Residual talc litigation remains: a $16 million talc verdict was upheld in a recent case, and media mentions of JNJ as “overvalued” could pressure sentiment if litigation headlines resume. Talc Verdict Stands

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.